2026 Immunization Vaccines 
Pharmaceutical Technology
JULY 18, 2022
GlaxoSmithKline (GSK) has signed an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to aid in protecting adults and children in the country. The company intends to supply both vaccines from its 230,000ft² Sainte-Foy facility in Quebec. .
pharmaphorum
FEBRUARY 7, 2022
The approval is some relief for Sanofi after a crop of pipeline disappointments last year, with Evaluate estimating the drug could make more than $500 million in sales in 2026. It is also being developed for other indications including immune thrombocytopenic purpura.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
FEBRUARY 21, 2023
threshold by 2026. Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines.
The FDA Law Blog
AUGUST 14, 2022
The number will begin in 2026 with 10 drug covered under Medicare Part D and will increase annually to 20 Part B and 20 Part D drugs by 2029 and thereafter, with the selected drugs accumulating from year to year. The same will be required under state Medicaid and CHIP programs by October 1, 2023.
pharmaphorum
OCTOBER 21, 2020
Merck & Co has built more momentum behind its attempt to depose Pfizer’s blockbuster pneumococcal conjugate vaccine Prevnar 13, with two new phase 3 trials backing its rival shot V114. It reiterated its plans to file for approval of the vaccine before the end of the year in the US.
BuzzRx
AUGUST 30, 2022
The Inflation Reduction Act will allow the government to negotiate lower prescription drug costs for some of the highest-priced, covered drugs between 2026 and 2029 and beyond. million who received the shingles vaccine. These are mainly drugs for which generic or biosimilar competitors are not available.
Expert insights. Personalized for you.
64 
Let's personalize your content